Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$50.14 USD

50.14
466,690

-2.32 (-4.42%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 250)

Industry: Medical Info Systems

Zacks News

Here's Why You Should Retain ResMed (RMD) Stock for Now

Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.

Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?

Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.

Smith+Nephew (SNN) Introduces Real Intelligence & CORI System

Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.

Here's Why You Should Hold on to Integra (IART) Stock for Now

Investors are optimistic about Integra (IART) given its better-than-expected results and robust performance of the CSS arm in the third quarter.

Allscripts' (MDRX) Services Leveraged by Next Level Urgent Care

Allscripts' (MDRX) Touchworks platform and Microsoft Azure hosting & services will be implemented across all Next Level Urgent Care's sites in Houston.

Here's Why You Should Hold on to Syneos Health (SYNH) for Now

Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.

3 Reasons Growth Investors Will Love Omnicell (OMCL)

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.

Here's Why You Should Add Omnicell (OMCL) To Your Portfolio

Investors are optimistic about Omnicell (OMCL) owing to its better-than-expected results in the third quarter and robust segmental performance.

Walgreens (WBA) to Offer COVID-19 Vaccine Booster Shots

Individuals aged 18 years or older are eligible to avail Pfizer, Moderna or Johnson & Johnson COVID-19 vaccine boosters from Walgreens' (WBA) stores.

NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?

NXGN vs. OMCL: Which Stock Is the Better Value Option?

Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?

Style Box ETF report for IJR

Should Vanguard S&P SmallCap 600 ETF (VIOO) Be on Your Investing Radar?

Style Box ETF report for VIOO

Should SPDRSP6 SC (SLY) Be on Your Investing Radar?

Style Box ETF report for SLY

Should SPDRSP6 SC (SLY) Be on Your Investing Radar?

Style Box ETF report for SLY

Omnicell (OMCL) Inks New Deal to Manage Controlled Substances

Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.

Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag

Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, View Slashed

Zimmer Biomet (ZBH) Q3 sales soft in Americas whereas EMEA and Asia-Pacific register growth at CER.

QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up

QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.

Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up

Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.

Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up

Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.

NXGN or OMCL: Which Is the Better Value Stock Right Now?

NXGN vs. OMCL: Which Stock Is the Better Value Option?

Omnicell (OMCL) Surpasses Q3 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 18.68% and 4.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stock Earnings on Nov 2: IDXX, STE & More

With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.

Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?

Style Box ETF report for IJT